Á. de Pablo Cárdenas

A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target

Prashant K. Srivastava, Jonathan van Eyll, Patrice Godard et al. · Nature Communications · 2018 · 106 citations · Full text

Pharmacy, Neuroscience, Systems Biology +13

Discovery of Novel Quaternary Ammonium Derivatives of (3<i>R</i>)-Quinuclidinol Esters as Potent and Long-Acting Muscarinic Antagonists with Potential for Minimal Systemic Exposure after Inhaled Administration: Identification of (3<i>R</i>)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane Bromide (Aclidinium Bromide)

María Prat, Dolors Fernández, María Antonia Buil et al. · Journal of Medicinal Chemistry · 2009 · 70 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Predictivity of dog co-culture model, primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans

Franck A. Atienzar, Eric Novik, Helga H.J. Gerets et al. · Toxicology and Applied Pharmacology · 2013 · 56 citations

Pharmacy, Pharmacology, Toxicology +17

In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

D. L. Price, Asma Khan, Rachel Angers et al. · npj Parkinson s Disease · 2023 · 33 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Discovery and Characterization of 4‘-(2-Furyl)-<i>N</i>-pyridin-3-yl-4,5‘-bipyrimidin-2‘-amine (LAS38096), a Potent, Selective, and Efficacious A_2BAdenosine Receptor Antagonist

Bernat Vidal, Arsenio Nueda, Cristina Esteve et al. · Journal of Medicinal Chemistry · 2007 · 32 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13